Overview


According to FutureWise analysis the market for Alcoholic Hepatitis Therapeutics is estimated to be US$ 0.83 billion in 2023, and is expected reach US$ 1.21 billion in 2031 at a CAGR of 6.1%.

Alcoholic hepatitis (AH) is liver inflammation caused by drinking alcohol. It is identified by the rapid onset of jaundice, malaise, anorexia, tender hepatomegaly, and systemic inflammatory response syndrome (SIRS) features. Alcoholic hepatitis most likely occurs in individuals who drink heavily over many years. Patients with alcoholic hepatitis are systemically ill with a high risk of nutritional deficiency, acute kidney injury (AKI), infection, and development of multiorgan failure (MOF) syndrome. For instance, approximately two-thirds of the US adult population drinks alcohol each year, and 7.4% report heavy drinking and meet the criteria for alcoholism. However, only a minority of heavy drinkers will develop alcoholic liver disease (ALD), likely due to environmental and genetic factors. To enhance clinical outcomes for patients with severe alcoholic hepatitis, it is crucial to accurately identify possible complications and understand the basic mechanisms underlying alcohol-induced liver damage.

Corticosteroids are the current primary treatment for severe alcoholic hepatitis (defined as DF ≥ 32, MELD ≥ 21, or presence of hepatic encephalopathy) in patients without contraindications for steroid treatment. Corticosteroids change the balance of cytokines, reducing pro-inflammatory cytokines, including tumor necrosis factor (TNF)-α, and increasing anti-inflammatory cytokines such as interleukin 10. Corticosteroids have potent anti-inflammatory effects. In cases of severe alcoholic hepatitis, there is significant inflammation in the liver. Corticosteroids can help reduce this inflammation, which may help improve liver function. They also have immunosuppressive properties, which can be beneficial in cases where the immune system is overactive and contributes to liver damage.

FutureWise Market Research has published a report that provides an insightful alcoholic hepatitis therapeutics market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, alcoholic hepatitis therapeutics market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Alkermes Inc.
  • Alfact Innovation
  • Conatus Pharmaceuticals Inc.
  • Dainippon sumitomo pharma Co. ltd.
  • Generon Corporation Ltd.
  • Immuron limited
  • Lupin Laboratories Ltd.
  • Intercept Pharmaceuticals Inc.
  • Teva Pharmaceuticals Ltd.
  • Sanofi-Aventis
  • Siesta Pharmaceuticals
  • Gilead Sciences Inc
  • ABBVIE Inc
  • Novartis
  • Roche

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Alcoholic Hepatitis Therapeutics Market:

  • In March 2022, Pfizer Inc. announced that it acquired Arena Pharmaceuticals, a company that develops new potential treatments for immune-inflammatory disease.

  • In March 2021, Mallinckrodt plc won the Manufacturing Leadership Award for outstanding achievement in two categories - Collaborative Innovation Leadership and Operational Excellence Leadership - from the National Association of Manufacturers (NAM).

The rising incidence of diverse therapeutics used in treating alcoholic hepatitis, such as corticosteroids, hemorrheologic agents, and others, is expected to propel the market growth. This comprehensive treatment emphasizes the evolving sophistication of medical interventions and offers healthcare providers a spectrum of options to personalize treatments based on individuals' needs and disease severity. This versatility in therapeutic approaches is further anticipated to drive the growth of the alcoholic hepatitis therapeutics market. Additionally, the increasing prevalence of alcohol consumption may increase the demand for alcoholic hepatitis therapeutics market during the forecast period. This surge in alcohol intake directly correlates with a rising prevalence of alcoholic liver diseases, leading to alcoholic hepatitis. As individuals continue to engage in excessive alcohol consumption, the incidence of these conditions rises in tandem, further creating a pressing demand for effective therapeutic interventions. However, the high-cost treatment of severe cases of alcoholic hepatitis, which often requires hospitalization and specialized care, may act as a significant barrier for many patients seeking treatment access. This financial pressure may impede their ability to receive timely medical intervention. Moreover, the stringent regulatory provisions for drug approval and compliance are expected to hamper the market growth. These demanding standards are crucial for ensuring patient safety and treatment efficacy, which may lead to prolonged approval procedures and higher development costs, potentially hindering some pharmaceutical companies from entering the market or investing in innovative therapeutic solutions.

By Drug Type

  • Monoclonal antibodies
  • Caspase protease inhibitor
  • Corticosteroids
  • Hemorheologic agents
  • Anabolic steroids
  • Hepatotropic hormones
  • Sulfhydryl agents
  • Other Drug Types

By Application

  • Mild Disease
  • Severe Disease

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies 

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. This is attributed to factors including increasing adoption of stem cell therapies, large patient population, growing awareness and diagnosis of alcoholic hepatitis due to the increasing prevalence of alcoholic hepatitis, rising R&D activities, the rising popularity of alcoholic hepatitis diseases such as cirrhosis fatty liver, growing favorable reimbursement environment for medical treatment, which has encouraged healthcare professionals to offer treatment for alcoholic hepatitis and has facilitated patient access to this treatment in the region is expected to drive the growth of the alcoholic hepatitis therapeutics market over the forecast period.

Drivers for Alcoholic Hepatitis Therapeutics Market

The growth and progress of the alcoholic hepatitis (AH) therapeutics market are propelled by several pivotal factors. A significant catalyst is the escalating prevalence of alcoholic liver diseases, particularly alcoholic hepatitis, attributable to the surge in alcohol consumption rates and unhealthy lifestyles. This prevalence surge underscores the imperative for efficacious therapeutic solutions to address this pressing public health concern. Another driving force stems from the glaring unmet medical need associated with alcoholic hepatitis. With its distressingly high mortality rate and limited treatment choices, a compelling demand emerges for pioneering and impactful therapeutics that can enhance patient outcomes and quality of life. The upward trajectory of global healthcare expenditure further amplifies these drivers. The growing focus on enhancing treatment modalities for severe liver conditions like alcoholic hepatitis is underpinned by escalating healthcare spending worldwide. This augmented financial commitment provides a crucial impetus for intensified research and development endeavors within this specialized therapeutic domain.

Restraints for Alcoholic Hepatitis Therapeutics Market

The alcoholic hepatitis therapeutics market encounters substantial impediments to its growth and advancement. Despite notable progress in research, a comprehensive grasp of the exact pathogenesis of alcoholic hepatitis remains elusive, thereby obstructing the creation of precise and efficacious therapeutic strategies. The intricate and diverse nature of disease presentation, coupled with varying degrees of severity among patients, complicates the establishment of universally applicable treatment approaches. The notable prevalence of high failure rates in clinical trials for new therapeutics arises from the disease's inherent complexity, the variability in patient responses, and the arduous task of demonstrating meaningful clinical benefits. Moreover, pursuing innovative treatments carries inherent risks of unforeseen adverse events or undesirable side effects, introducing potential hurdles in delayed regulatory approvals and limited market acceptance. Notably, the accessibility and affordability of advanced healthcare services are unevenly distributed across different regions, posing significant challenges for patients with alcoholic hepatitis, impeding their ability to access optimal and timely care.

Opportunities for Alcoholic Hepatitis Therapeutics Market

The alcoholic hepatitis therapeutics market is poised with promising opportunities to propel its growth and evolution. These include the potential for targeted therapies through advancing our understanding of alcoholic hepatitis's molecular mechanisms, leading to personalized treatments with optimized outcomes and reduced side effects. Collaborative endeavors among pharmaceutical entities, research institutions, and regulatory bodies can hasten novel therapy development, streamlining market entry. Further, investments in healthcare infrastructure, especially in regions with high alcoholic hepatitis prevalence, can broaden access to advanced diagnostics and treatments. Noninvasive diagnostic tools, such as imaging and serum biomarkers, offer avenues for precise diagnosis and monitoring. Additionally, regulatory support via expedited pathways and incentives can incentivize pharmaceutical innovation and investment, driving progress in addressing this critical health concern.

Trends for Alcoholic Hepatitis Therapeutics Market

Several key trends are significantly shaping the alcoholic hepatitis therapeutics market. Biologics, including monoclonal antibodies, are showing promise in selectively targeting disease-related molecules and pathways. Digital health solutions like Alcoholic Hepatitis Therapeutics and remote monitoring are being integrated to enhance patient engagement and real-time data collection. Combination therapies addressing multiple disease mechanisms are being explored to improve treatment efficacy. Ongoing efforts in biomarker discovery and noninvasive diagnostics are gaining traction for early detection and disease monitoring. Real-world evidence and outcomes research provide valuable insights into treatment effectiveness across diverse patient populations. Additionally, there's a growing emphasis on lifestyle modifications and supportive care alongside pharmacological interventions to promote long-term liver health and overall well-being. These trends collectively signify a dynamic shift in the management and treatment landscape of alcoholic hepatitis.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • FutureWise research report will help you understand the growth prospects, key trends, and data points affecting the market's growth. 
  • A detailed review of strategies being opted by the players in this market, and a thorough market share registered by the key companies globally as well as on a regional basis.

  • To provide with an exhaustive analysis on the of Alcoholic Hepatitis Therapeutics Market By Drug Type, By Application, By Distribution Channel and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Alcoholic Hepatitis Therapeutics Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Alcoholic Hepatitis Therapeutics Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Alcoholic Hepatitis Therapeutics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Alcoholic Hepatitis Therapeutics Market, By Drug Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Monoclonal antibodies
        2. Caspase protease inhibitor
        3. Corticosteroids
        4. Hemorheologic agents
        5. Anabolic steroids
        6. Hepatotropic hormones
        7. Sulfhydryl agents
        8. Other Drug Types

  • 8.   Alcoholic Hepatitis Therapeutics Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Mild Disease
        2. Severe Disease

  • 9.   Alcoholic Hepatitis Therapeutics Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies

  • 10.   North America Alcoholic Hepatitis Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Alcoholic Hepatitis Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Alcoholic Hepatitis Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Alcoholic Hepatitis Therapeutics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Alkermes Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Alfact Innovation
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Conatus Pharmaceuticals Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Dainippon sumitomo pharma Co. ltd.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Generon Corporation Ltd.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Immuron limited
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Intercept Pharmaceuticals Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Teva Pharmaceuticals Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Sanofi-Aventis
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Siesta Pharmaceuticals
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Gilead Sciences Inc
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. ABBVIE Inc
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Novartis
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Roche
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Related Market

Nonalcoholic Steatohepatitis (NASH) Market

Read More

Non-Alcoholic Steatohepatitis (Nash) Therapeutics And Diagnostics Market

Read More

Nonalcoholic Steatohepatitis Drugs Pipeline Market

Read More
Partner

Our Clients